Clinical trials: Esrd
End Stage Renal Disease
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb) levels in chronic hemodialysis subjects who…
- Trial name
- PRIME (NCT01286012)
- Testing
- Soluble Ferric Pyrophosphate in liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 108 people
- Sponsor
- Rockwell Medical Technologies, Inc.
End-Stage Renal Disease
Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis
This study is to evaluate the safety and tolerability of the AKST1210 column at blood-flow rates greater than 250 mL/min in subjects with end-stage renal disease (ESRD) undergoing hemodialysis (HD).
- Trial name
- NCT04985383
- Testing
- AKST1210 S-15 at 250 mL/min, AKST1210 S-15 at 450 mL/min, AKST1210 S-25 at 250 mL/min
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.
Chronic Kidney Disease
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with…
- Trial name
- ZENITH-CKD (NCT04724837)
- Testing
- Zibotentan, Dapagliflozin
- Where
- 164 sites in United States, Argentina and 17 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Anemia, End Stage Renal Disease
Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant
In this End Stage Renal Disease (ESRD) patients who need Erythropoietin (epo) hormone will get it by a small implant of skin using their own skin, the implant will be treated in the laboratory and programmed to secrete Epo.
- Trial name
- NCT01555515
- Testing
- implantation of autologous skin graft after ex-vivo treatment, Subcutan implantation of autologus skin graft after ex-vivo treatment
- Volunteers
- 4 people
- Sponsor
- Medgenics Medical Israel Ltd.
Diabetes, End Stage Renal Disease
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula…
- Trial name
- MAFASA (NCT06190717)
- Testing
- EchoMark/EchoSure, Standard of Care
- Where
- 23 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sonavex, Inc.
Acute Kidney Injury, Renal Failure
Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation
The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments.
- Trial name
- RCA-Flux (NCT07679568)
- Testing
- multiFlux 160 hemofilter with regional heparin anticoagulation, multiFlux 160 hemofilter with RCA with regional citrate anticoagulation, multiFlux 130 hemofilter with regional heparin anticoagulation
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Renal Failure Chronic Requiring Hemodialysis
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
The purpose of this study is to confirm the safety and efficacy of Soluble Ferric Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in anemic adult patients with chronic kidney disease (CKD)…
- Trial name
- NCT01322347
- Testing
- Soluble Ferric Pyrophosphate (SFP), Standard dialysate
- Where
- 40 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Obesity &Amp; Overweight, Chronic Kidney Disease
UBT251 Injection Phase II Clinical Study (CKD)
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
- Trial name
- NCT07134335
- Testing
- UBT251
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Anemia, Chronic Kidney Disease
A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)
This study will define an effective starting dose for subcutaneous administration of MK2578 to correct anemia in erythropoiesis-stimulating agent (ESA)-naive patients with chronic kidney disease (CKD) who are not on dialysis…
- Trial name
- NCT00968617
- Testing
- MK2578, Comparator: darbepoetin alfa
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Disease
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia
The purpose of this study is to characterize the safety and efficacy of repeat doses of compound 1278863A in subjects with anemia.
- Trial name
- NCT01047397
- Testing
- 1278863A
- Where
- 37 sites in Australia, India and 2 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease
Comparison of Individualized Sodium Management Versus Standard Treatment in Hemodialysis
The SODIAH study is designed with the aim to assess the impact of isonatremic dialysis on interdialytic weight gain, fluid status, intradialytic hemodynamic stability, and incidence of intradialytic morbid events in dialysis…
- Trial name
- SODIAH (NCT06341452)
- Testing
- Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control
- Where
- Czechia
- Volunteers
- 130 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hyperphosphatemia, Kidney Failure
EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)
The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
- Trial name
- NCT00211978
- Testing
- calcium acetate
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Nabi Biopharmaceuticals
Coronary Artery Disease (CAD), Renal Impairment
Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography
The study is to evaluate and compare the effects on kidney function of three iodinated contrast media (CM) in patients at risk of kidney damage evaluating serum creatinine (Scr) concentrations up to three days after CM…
- Conditions
- Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
- Trial name
- NCT00335101
- Testing
- Iodixanol, Ioversol, Iopromide
- Where
- 2 sites in United States, Germany
- Sponsor
- GE Healthcare
Chronic Hepatitis C Virus
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
The purpose of this multicenter, single-arm, combination-drug study, which includes 12 weeks of treatment and 24 weeks of follow-up, is to evaluate the safety, efficacy and pharmacokinetics of ombitasvir/paritaprevir/ritonavir in…
- Trial name
- GIFT-R (NCT02806362)
- Testing
- Ombitasvir/paritaprevir/ritonavir
- Sponsor
- AbbVie
Renal Failure, CVVHD
Analysis of Paediatric Treatments With multiFiltratePRO
This clinical study evaluates the performance of the MultifiltratePro in pediatric mode for Continuous Venovenous Hemodiafiltration (CVVHD) in children.
- Trial name
- ECHOped (NCT06603324)
- Testing
- CVVHD treatment in paediatric mode with multiFiltratePRO
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 43 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Chronic Kidney Disease, Diabetic Nephropathy
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Prospective, Randomized, Double-Blind, Parallel Design, Placebo-Controlled Multicenter Study. The study objectives are to evaluate efficacy and safety, including thoracic bioimpedance, of once daily administration of atrasentan…
- Trial name
- NCT01399580
- Testing
- Atrasentan
- Where
- 28 sites in United States
- Volunteers
- 48 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Acute Kidney Injury, Abdominal Compartment Syndrome
Physiologic Signals and Signatures With the Accuryn Monitoring System (The Accuryn Registry)
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients.
- Conditions
- Acute Kidney Injury, Abdominal Compartment Syndrome, Intraabdominal Hypertension, Cardiovascular Surgery
- Trial name
- NCT04585555
- Testing
- Accuryn Monitoring System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Potrero Medical
Renal Failure, Chronic, End-Stage Renal Disease
PK of Serelaxin in Severe Renal Impairment and ESRD
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD)…
- Trial name
- CRLX030A2102 (NCT01875523)
- Testing
- Serelaxin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Injury of Kidney, Acute Renal Failure
A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery
This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 8-10 centers in the United States and Switzerland.
- Trial name
- NCT00554359
- Testing
- I5NP (a small interfering RNA)
- Where
- 11 sites in United States, Israel and 1 more
- Volunteers
- 16 people
- Sponsor
- Quark Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.